<DOC>
	<DOCNO>NCT00733889</DOCNO>
	<brief_summary>The purpose study determine efficacy an safety combination cetuximab chemotherapy ( docetaxel , cisplatin , 5-fluorouracil ) neoadjuvant therapy follow concomitant chemoradiotherapy ( cisplatin ) plus cetuximab patient locoregional esophageal carcinoma</brief_summary>
	<brief_title>A Study Evaluate Combination Cetuximab Chemotherapy Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab Locoregional Esophageal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Informed consent form sign perform study 's specific procedure . Age &gt; 18 &lt; 70 . Karnofsky performance status &gt; 70 % upon inclusion study . Life expectancy 3 month . Histologically confirm diagnosis squamous cell carcinoma adenocarcinoma oesophagus gastroesophageal junction . The disease must confine oesophagus gastroesophageal junction perioesophageal region . There must tumor extension beyond 2 cm stomach . Stages II III . The patient must T1N1M0 T24 ; N ; M0 . The exception would patient stage IVA : oesophageal carcinoma upper thoracic region metastasis cervical lymph node ( M1a ) oesophageal carcinoma low thoracic region metastasis celiac lymph node ( M1a ) , provide disease remain within radiotherapy field . Presence unidimensionally measurable and/or assessable lesion Neutrophils &gt; 1500/mm3 , platelet count &gt; 150,000/mm3 haemoglobin &gt; 10 g/dl . Adequate renal function : serum creatinine &lt; 120 micromol/l ( 1.4 mg/dl ) ; value &gt; 120 micromol/l ( 1.4 mg/dl ) creatinine clearance must &gt; 65 ml/min . Adequate liver function : total bilirubin &lt; 1 x NUL ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 x NUL ; alkaline phosphatase ( AP ) &lt; 5 x NUL . Patients AST and/or ALT &gt; 1.5 &lt; 2.5 x NUL AP &gt; 1.5 x NUL &lt; 5 x NUL eligible . Serum calcium &lt; 1.25 x normal upper limit ( NUL ) . Adequate nutritional status : weight loss &lt; 20 % regular weight albumin &gt; 35 g/l . Total oral and/or enteral intake least 1700 calories/day . Use effective contraceptive method patient sex risk conception and/or pregnancy . Availability tumour tissue immunohistochemical analysis EGFR expression biological marker . Patients tracheooesophageal fistula direct invasion tracheal mucosa major bronchus eligible . Bronchoscopy ( biopsy cytology lesion see ) require order rule fistula and/or direct invasion primary tumour &lt; 30 cm incisor . Bronchoscopy also require primary tumour show carina image study . Prior thoracic radiotherapy and/or systemic chemotherapy and/or oesophageal surgery . Patients multiple carcinoma oesophagus . Diagnosis cancer previous 5 year exception appropriately treat carcinoma situ uterine cervix and/or basal cell carcinoma skin . Systemic , chronic concomitant immune treatment , anticancer hormone therapy . Other concomitant cancer treatment . Active infection ( infection require intravenous antibiotic ) , include active tuberculosis diagnose HIV . Uncontrolled hypertension define systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 130 mmHg rest . Active , uncontrolled , gastric duodenal peptic ulcer . Chronic obstructive pulmonary disease require hospitalisation 6 month prior inclusion study . History atrioventricular arrhythmia and/or cardiac failure and/or second third degree heart block . Clinically significant coronary artery disease history myocardial infarction last 12 month . Peripheral neuropathy grade &gt; 2 NCICCTG aetiology . Hearing disorder grade &gt; 2 NCICCTG aetiology . Any disease medical disorder suggest patient able complete study . Any psychological disorder suggest complete treatment possible . Pregnancy ( absence must confirm serum HCGbetatest ) lactation . Known drug abuse ( exception mild moderate consumption alcohol upon inclusion study ) . Known allergic reaction component study treatment . Prior treatment monoclonal antibody signal transduction inhibitor EGFRtargeted treatment . Evidence another cancer , exception carcinoma situ uterine cervix and/or basal cell carcinoma skin . Any experimental treatment 30 day prior inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>esophageal carcinoma</keyword>
	<keyword>cetuximab</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>5-fluorouracil</keyword>
</DOC>